Display options
Cite
Brunton SA. The changing shape of type 2 diabetes. Medscape J Med. 2008;10(6):143; quiz 143
Brunton, S. A. (2008). The changing shape of type 2 diabetes. Medscape journal of medicine, 10(6), 143; quiz 143.
Brunton, Stephen A. "The changing shape of type 2 diabetes." Medscape journal of medicine vol. 10,6 (2008): 143; quiz 143.
Brunton SA. The changing shape of type 2 diabetes. Medscape J Med. 2008 Jun 18;10(6):143; quiz 143. PMID: 18679554; PMCID: PMC2491685.
Copy Download .nbib Format: NLM
Share it on

Medscape J Med. 2008 Jun 18;10(6):143; quiz 143.

The changing shape of type 2 diabetes.

Medscape journal of medicine

Stephen A Brunton

Affiliations

  1. Stamford Hospital, Columbia University, Charlotte, North Carolina; Cabarrus Family Medicine Residency Program, Concord, North Carolina, USA.

PMID: 18679554 PMCID: PMC2491685

Abstract

CONTEXT: Type 2 diabetes is primarily a disease that affects late-middle-aged and elderly individuals. Due to increasing affluence, lifestyle changes, and obesity, however, it is also affecting younger age groups. Therefore, treatment recommendations may need to be revised to reflect these changes. Fortunately, various new treatment options, including insulin analogs with more physiologic time-action profiles and drugs that target the incretin system, are now available.

EVIDENCE ACQUISITION: This review was based on a PubMed literature search done in August 2007, using relevant search terms.

EVIDENCE SYNTHESIS: Improving diet and increasing physical activity are important therapeutic interventions in diabetes and associated conditions. However, many people find it difficult to maintain lifestyle changes, which is why the American Diabetes Association recommends lifestyle intervention plus metformin following initial diagnosis. Current guidelines recommend a stepwise approach, with additional oral antidiabetic drugs (OADs) being added as the disease progresses. Insulin therapy should be initiated once OADs fail to control hyperglycemia, as there is good evidence that intensive therapy, with strict glycemic targets, can reduce the long-term microvascular complications that are associated with poorly controlled diabetes. In addition, while the evidence is less conclusive, intensive therapy may also improve long-term macrovascular comorbidities.

CONCLUSIONS: It is important that patients with diabetes receive the most effective therapy for maintaining glycemic control and that treatment is modified or augmented in those who are not achieving appropriate glycemic goals. Only by maintaining long-term, effective glycemic control can the microvascular and macrovascular comorbidities associated with diabetes be minimized.

References

  1. Med J Aust. 2007 May 7;186(9):461-5 - PubMed
  2. Lancet. 1999 Aug 21;354(9179):617-21 - PubMed
  3. Am J Manag Care. 2007 Apr;13 Suppl 2:S47-54 - PubMed
  4. Endocrinol Metab Clin North Am. 2006 Dec;35 Suppl 1:3-5; discussion 17-19 - PubMed
  5. Diabetes Obes Metab. 2005 Jan;7(1):56-64 - PubMed
  6. Clin Chem Lab Med. 2003 Sep;41(9):1266-78 - PubMed
  7. Nutr Health. 1997;11(3):149-57 - PubMed
  8. Nat Rev Drug Discov. 2006 Nov;5(11):919-31 - PubMed
  9. Diabetes Care. 2004 May;27(5):1047-53 - PubMed
  10. Mayo Clin Proc. 2003 Apr;78(4):411-3 - PubMed
  11. Eur J Endocrinol. 2004 Oct;151 Suppl 2:T23-7; discussion T29-30 - PubMed
  12. N Engl J Med. 2005 Dec 22;353(25):2643-53 - PubMed
  13. Aust N Z J Public Health. 2007 Apr;31(2):177-83 - PubMed
  14. Nature. 2001 Dec 13;414(6865):782-7 - PubMed
  15. Curr Pharm Des. 2001 Sep;7(14):1303-25 - PubMed
  16. J Clin Endocrinol Metab. 2000 Aug;85(8):2970-3 - PubMed
  17. Diabetes Care. 2004 Jun;27(6):1335-42 - PubMed
  18. Am J Hum Genet. 1962 Dec;14:353-62 - PubMed
  19. Neth J Med. 2007 Feb;65(2):60-4 - PubMed
  20. Indian J Med Res. 2007 Mar;125(3):345-54 - PubMed
  21. Biomed Environ Sci. 2002 Sep;15(3):245-52 - PubMed
  22. Lancet. 2006 Nov 11;368(9548):1673-9 - PubMed
  23. Lancet. 1998 Sep 12;352(9131):837-53 - PubMed
  24. BMJ. 2006 Aug 19;333(7564):362-3 - PubMed
  25. N Engl J Med. 2007 Jul 5;357(1):28-38 - PubMed
  26. Am J Clin Nutr. 2003 Dec;78(6):1120-7 - PubMed
  27. N Engl J Med. 2007 Feb 1;356(5):437-40 - PubMed
  28. Diabetes Care. 1997 Jul;20(7):1183-97 - PubMed
  29. J Pediatr. 2005 May;146(5):693-700 - PubMed
  30. J Clin Endocrinol Metab. 2001 Jun;86(6):2899-902 - PubMed
  31. JAMA. 2003 Oct 8;290(14):1884-90 - PubMed
  32. Diabetes Care. 2006 Sep;29(9):2114-6 - PubMed
  33. JAMA. 2006 Apr 5;295(13):1549-55 - PubMed
  34. Clin Drug Investig. 2007;27(4):279-85 - PubMed
  35. N Engl J Med. 2007 Jun 14;356(24):2457-71 - PubMed
  36. Am J Clin Nutr. 2004 Jul;80(1):51-7 - PubMed
  37. Rev Diabet Stud. 2005 Spring;2(1):35-9 - PubMed
  38. Lancet. 2007 May 26;369(9575):1823-1831 - PubMed
  39. Metab Syndr Relat Disord. 2004 Jun;2(2):105-13 - PubMed
  40. Diabetologia. 2004 Apr;47(4):622-9 - PubMed
  41. Endocr Pract. 2007 May-Jun;13(3):260-8 - PubMed
  42. Diabetes. 2006 Apr;55(4):1114-20 - PubMed
  43. Proc Nutr Soc. 2007 Feb;66(1):82-95 - PubMed
  44. Diabetes Care. 1997 Apr;20(4):537-44 - PubMed
  45. Clin Ther. 2006 Oct;28(10):1569-81 - PubMed
  46. Diabetes Obes Metab. 2007 May;9(3):418-27 - PubMed
  47. J Investig Med. 2007 Mar;55(2):62-8 - PubMed
  48. JAMA. 2002 May 15;287(19):2563-9 - PubMed
  49. Diab Vasc Dis Res. 2007 Mar;4(1):32-8 - PubMed
  50. Circulation. 2005 Mar 22;111(11):1448-54 - PubMed
  51. Clin Ther. 2003 Nov;25(11):2836-48 - PubMed
  52. J Clin Invest. 1999 Sep;104(6):787-94 - PubMed
  53. Diabetes Care. 2003 Nov;26(11):3160-7 - PubMed
  54. Diabetes Care. 2007 Jun;30(6):1487-93 - PubMed
  55. N Engl J Med. 2002 Feb 7;346(6):393-403 - PubMed
  56. Diabetes Care. 1997 May;20(5):844-7 - PubMed
  57. MedGenMed. 2007 Apr 16;9(2):12 - PubMed
  58. BMJ. 2000 Aug 12;321(7258):405-12 - PubMed
  59. Diabetes Care. 2006 Aug;29(8):1963-72 - PubMed
  60. Diab Vasc Dis Res. 2006 May;3(1):7-11 - PubMed
  61. N Engl J Med. 2002 Mar 14;346(11):854-5 - PubMed
  62. Diabetes Care. 1999 Jun;22(6):920-4 - PubMed

MeSH terms

Publication Types